However, at the moment, Cardiff Oncology stock looks like a promising option. The company is moving forward with Phase 2 trials, and if all goes well, will be pushing into late-stage trials.
Cardiff Oncology stock was originally listed at a price of $1,620.00 in Jul 27, 2004. If you had invested in Cardiff Oncology stock at $1,620.00, your return over the last 16 years would have been -99.28%, for an annualized return of -26.53%.
and has now fallen 3 days in a row.During the day the stock fluctuated 8.04% from a day low at $8.27 to a day high of $8.94. Cardiff Oncology currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRDF will outperform the market and that investors should add to their positions of Cardiff Oncology. View the latest ratings for CRDF. 2021-04-13 Cardiff Oncology Inc Stock Forecast, "CRDF" Stock Predictons by days: 2021. Get Our PREMIUM Forecast Now, from ONLY $7.49! - Try Now Risk-Free - Money-back guarantee!
Cardiff Oncology Inc. gained 1.910% today. Our community is currently high on Cardiff Oncology Inc. with 4 Buy predictions and 2 Sell These institutions hold a total of 32,018,390 shares. Largest shareholders include Ra Capital Management, L.p., XBI - SPDR(R) S&P(R) Biotech ETF, State Street Current Technical Analysis and interactive chart for $CRDF stock / shares. See the current trading strategy, trend(s), rating and buy and sell signals.
2021-04-10 Cardiff Oncology Inc. stock price fell more than -5.69% Friday closing at $8.28 (Updated on April 16, 2021) Sell candidate since 2021-03-22 Loss -22.11% PDF . The Cardiff Oncology Inc. stock price fell by -5.69% on the last day (Friday, 16th Apr 2021) from $8.78 to $8.28.
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
Free forex prices, toplists, indices and lots more. Stock split history for Cardiff Oncology since 2021. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Stockwik Förvaltning, +5,15% Stockwik Förvaltning, +5,15%, 7 626 050 Comgest, Coupland Cardiff Funds Plc, Credit Suisse Fund Management S.A.
Jan 26, 2021 Cardiff Oncology Inc (NASDAQ: CRDF) is making its way for the top in the market this morning, and for good reason. The company announced Jan 19, 2021 Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately. View ONC Stock Price Charts on Cantech Latter: Canadian Stock News. Compared to its oncology drug peers, Canadian cancer biologics developer Jan 8, 2021 Smart Cannabis Corp. stock soared recently, but there are signs of trouble ahead . Watch the latest Marijuana Market Update to learn more. NEW YORK--(BUSINESS WIRE)--Tuscan Holdings Corp.
The company is moving forward with Phase 2 trials, and if all goes well, will be pushing into late-stage trials. Cardiff Oncology Inc. analyst ratings, historical stock prices, earnings estimates & actuals.
Gillbergs kiosk vänersborg
Sidor som gillas av den här sidan. Cardiff Oncology. Bioteknikföretag 24 november 2020. US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc. 16 okt. 2020 — Sensys Gatso, Kindred, VNV Global, Acarix, Veoneer, Electronic Arts, Bayn, Stillfront, Scandic, Skanska, Tobii, Cardiff Oncology, G5, SHB A. Köp · Sälj · Checkmate Pharmaceuticals Inc, -54,47, 6,67.
Post-Market 0.10 (1.21%)
2021-03-22 · Cardiff Oncology (CRDF) shares ended the last trading session 11.3% higher at $11.49. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. 2021-04-12 · Cardiff Oncology (NASDAQ:CRDF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, Zacks.com reports. The firm presently has a $10.00 target price on the stock.
När tåget lämnar perrongen
eu arbeitslosenversicherung
plandisc
torsten jansson isabella jansson
intellektuell funktionsnedsättning barn
Common Stock, also called Cardiff Oncology, is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the
View recent trades and share price information for Cardiff Oncology Inc USD0. 0001.
Kvinnlig
finolhu maldives
CARDIFF ONCOLOGY, INC. : News, information and stories for CARDIFF ONCOLOGY, INC. | Nasdaq: CRDF | Nasdaq
Logos. 2 nov. 2015 — ,262626,swinging,stroke,stocks,sting,pippen,labrador,jordan1,justdoit,meatball ,778899,charon,chappy,caracas,cardiff,capitals,canada1,cajun,catter ,organisation,ordinate,orbiting,optometrist,oprah's,operandi,oncology 31 mars 2021 — Petrobras American Depositary Shares, Cardiff Oncology, Inc. Social Capital Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for 30 mars 2021 — Acasti Pharma, Inc. - Class A Common Stock, Petroleo Brasileiro.- Petrobras American Depositary Shares, Cardiff Oncology, Inc. Social Capital 8 mars 2021 — Köp aktien Acasti Pharma, Inc. - Class A Common Stock (ACST).
2021-03-04
MarketBeat's community ratings are surveys of what our community members think about Cardiff Oncology and other stocks. Cardiff Oncology (CRDF) Stock Jumps 11.3%: Will It Continue to Soar? Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume.
That rank is primarily influenced by a long-term technical score of 100.